Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: Joint United States and Japan study of UFT/LV

Journal of Clinical Oncology

Volumn 22, Issue 17, 2004, Pages 3466-3474

  Shirao, Kuniaki ^a   Hoff, P M ^b   Ohtsu, A ^b   Loehrer, P J ^b   Hyodo, I ^b   Wadler, S ^b   Wadleigh, R G ^b   O'Dwyer, P J ^b   Muro, K ^b   Yamada, Y ^b   Boku, N ^b   Nagashima, F ^b   Abbruzzese, J L ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; UFT; URACIL; ANTINEOPLASTIC AGENT; TEGAFUR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; INCIDENCE; JAPAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UNITED STATES; ADULT; AGED; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; TEGAFUR; UNITED STATES; URACIL;

EID: 4444243813     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.017     Document Type: Article

References (31)

1. Scheithauer W, Rosen H, Kornek G-V, et al: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
2. Douillard JY, Cunningham D, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 355:1041-1047, 2000
3. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 20:124a, 2001 (abstr 494)
4. Saltz L, Cox J, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
5. Sargent D, Niedzwiecki D, O'Connell M, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001
6. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a G1 Intergroup study. Proc Am Soc Clin Oncol 21:128a. 2002 (abstr 511)
7. Toide H, Akiyoshi H, Minato Y, et al: Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 68:553-560, 1977
8. Fujii S, Kitano S, Ikenaka K, et al: Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 6:377-384, 1979
9. Pazdur R, Lassere Y, Diaz-Canton E, et al: Phase I trials of uracil-tegafur (UFT) using 5 and 28 days administration schedules: Demonstration of schedule-dependent toxicities. Anticancer Drugs 7:728-733, 1996
10. Muggia FM, Wu X, Spicer D, et al: Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 2:1461-1467, 1996
11. Pazdur R, Lassere Y, Rhodes V, et al: Phase II study of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal cancer. J Clin Oncol 12:2296-2300, 1994
12. Saltz LB, Leicheman CG, Young CW, et al: A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. Cancer 75:782-785, 1995
13. Borner MM, Schoffski P, de Wit R, et al: Patients preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349-358, 2002
14. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616, 2002
15. Carmichael J. Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parental fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617-3627, 2002
16. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharamcol 22:333-338, 1988
17. Miller A, Hoogstraten B, Straguet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
18. National Cancer Institute Common Toxicity Criteria, http://ctep.cancer. gov/reporting/ctc-3 .html
19. Marunaka T, Umeno Y, Yoshida K, et al: High-pressure liquid chromatographic determination of tegafur (1-(tetrahydro-2-furanyl)-5- fluorouracil) and uracil in biological materials after oral administration of uracil plus tegafur. J Pharm Sci 69:1296-1300, 1980
20. Anderson LW, Parker RJ, Collins JM, et al: Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J Chromatogr 581:195-201, 1992
21. Etienne MC, Speziale N, Milano G: HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. Clin Chem 39:82-86, 1993
22. Belz S, Frickel C, Wolfram C, et al: High-performance liquid chromatographic determination of methotrexate, 7-hydromethotrexate, 5-methyltetrahydrofolic acid and folinic acid in serum and cerebrospinal fluid. J Chromatogr B Biomed Appl 661:109-118, 1994
23. Gonzalez-Baron M, Feliu J, de la Gandara I, et al: Efficacy of oral tegafur modulation byuracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31A:2215-2219, 1995
24. Gonzalez-Baron M, Feliu J, Garcia Giron C, et al: UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 54:24-29, 1997 (suppl 1)
25. Feliu J, Gonzalez-Baron M, Espinosa E, et al: Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal cancer. Cancer 79:1884-1889, 1997
26. Abad A, Navarro M, Sastre J, et al: A preliminary report of a phase Il trial: UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology (Huntingt) 11:53-57, 1997 (suppl 10)
27. Sanchiz F, Milla A: Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 24:322-326, 1994
28. Malik ATA, Talbot D, Clarke PI, et al: Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 62:1023-1025, 1990
29. McCollum AD, Catalano PJ, Haller DG, et al: Outcomes and toxicity in African-American and Caucasian patients in randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 94:1160-1167, 2002
30. Meropol NJ, Sonnichsen DS, Birkhofer MJ, et al: Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 43:221-226, 1999
31. Damle B, Ravandi F, Kaul S, et al: Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 7:517-523, 2001